SCHEMBL5318326

SCHEMBL5318326

CCCN1CCC(NCCOC)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.47
DRD2 P14416 4/20 0.40
KDM1A O60341 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
EPHX1 P07099 1/20 0.38
EPHX2 P34913 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP2C9 P11712 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CARM1 Q86X55 1/20 0.37
PRMT6 Q96LA8 1/20 0.37
RAD52 P43351 1/20 0.37
MITF O75030 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316790 0.86 KDM4E (0.44) KDM1ASMN1; SMN2KDM4EALDH1A1EPHX1
SCHEMBL20492763 0.83 PABPC1 (0.45) PABPC1DRD2EPHX1EPHX2L3MBTL1
SCHEMBL190633 0.82 EHMT2 (0.40) KDM4EALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL20492912 0.80 GNAI3 (0.45) PABPC1DRD2EPHX1EPHX2L3MBTL1
SCHEMBL18873644 0.79 KDM1A (0.47) PABPC1KDM1ACARM1PRMT6
SCHEMBL20627623 0.79 KDM1A (0.40) PABPC1KDM1ACYP2C9HRH3CARM1
SCHEMBL22878502 0.77 PABPC1 (0.46) PABPC1DRD2EPHX1EPHX2L3MBTL1
SCHEMBL4761390 0.77
SCHEMBL24171160 0.77 KDM4E (0.37) KDM4EALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL20492671 0.76 MEN1 (0.43) PABPC1DRD2EPHX1EPHX2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007069053-A1 BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-06-21 WO claimed
US-12605373-B2 Methods and compositions of inhibiting DCN1-UBC12 interaction MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2026-04-21 US disclosed
US-20250120965-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2025-04-17 US disclosed
US-11963954-B2 Methods and compositions of inhibiting DCN1-UBC12 interaction MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2024-04-23 US disclosed
US-20230021224-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-01-19 US disclosed
EP-3349743-B1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION ST JUDE CHILDRENS RES HOSPITAL (US) 2022-04-06 EP disclosed
US-11116757-B2 Methods and compositions of inhibiting DCN1-UBC12 interaction MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-09-14 US disclosed
US-20210069172-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-03-11 US disclosed
US-20180256558-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2018-09-13 US disclosed
EP-3349743-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION St. Jude Children's Research Hospital (US) 2018-07-25 EP disclosed
WO-2017049295-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-03-23 WO disclosed
WO-2007069053-A1 BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180256558-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION UBQLN1, CUL1, DCUN1D1 PABPC1 283/4885DRD2 4060/4885KDM1A 364/4885
US-12605373-B2 Methods and compositions of inhibiting DCN1-UBC12 interaction CUL3, CUL1, CUL5 PABPC1 414/4885DRD2 4702/4885KDM1A 757/4885
US-20230021224-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION UBQLN1, CUL1, DCUN1D1 PABPC1 283/4885DRD2 4060/4885KDM1A 364/4885
US-11116757-B2 Methods and compositions of inhibiting DCN1-UBC12 interaction UBQLN1, CUL1, DCUN1D1 PABPC1 283/4885DRD2 4060/4885KDM1A 364/4885
US-11963954-B2 Methods and compositions of inhibiting DCN1-UBC12 interaction UBQLN1, CUL1, DCUN1D1 PABPC1 283/4885DRD2 4060/4885KDM1A 364/4885
US-20210069172-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION UBQLN1, CUL1, DCUN1D1 PABPC1 283/4885DRD2 4060/4885KDM1A 364/4885
US-20250120965-A1 METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION UBQLN1, CUL1, DCUN1D1 PABPC1 283/4885DRD2 4060/4885KDM1A 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.